New York, October 21, 2016 -- Moody's Investors Service commented that the Food and Drug Administration's (FDA) proposal to withdraw approval of the Abbreviated New Drug Applications (ANDAs) for methylphenidate HCl ER tablets (the generic version of Concerta) is credit negative for Mallinckrodt International Finance SA (Ba3 stable) and Lannett Company Inc. (B2 stable). There is no change to either company's rating or outlook.

Vollständigen Artikel bei Moodys lesen